The Myc/macrophage tango: Oncogene-induced senescence, Myc style

Seminars in Cancer Biology

Volumn 21, Issue 6, 2011, Pages 377-384

  Lee, Soyoung ^a,b   Schmitt, Clemens A ^a,b   Reimann, Maurice ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

Author keywords

Apoptosis; Lymphoma; Macrophages; Mouse Models; Myc; Oncogenes; Senescence; TGF

Indexed keywords

CHEMOKINE RECEPTOR CXCR2; SHORT HAIRPIN RNA; TRANSFORMING GROWTH FACTOR BETA;

APOPTOSIS; CANCER CELL; CD4+ T LYMPHOCYTE; CELL AGING; CELL POPULATION; CELL PROLIFERATION; CYTOKINE RELEASE; CYTOKINE RESPONSE; DNA DAMAGE; DNA SYNTHESIS; GENE FUNCTION; GENE INACTIVATION; GENE OVEREXPRESSION; GENE SILENCING; GENE TARGETING; IMMUNE RESPONSE; INNATE IMMUNITY; NONHUMAN; ONCOGENE; ONCOGENE C MYC; ONCOGENE MYC; PHENOTYPE; REVIEW;

CELL AGING; GENES, MYC; HUMANS; ONCOGENES;

EID: 82755197066     PISSN: 1044579X     EISSN: 10963650     Source Type: Journal    
DOI: 10.1016/j.semcancer.2011.10.002     Document Type: Review

References (73)

1. Schmitt C.A. Senescence, apoptosis and therapy-cutting the lifelines of cancer. Nat Rev Cancer 2003, 3:286-295.
2. Serrano M., Lin A.W., McCurrach M.E., Beach D., Lowe S.W. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 1997, 88:593-602.
3. Zhu J., Woods D., McMahon M., Bishop J. Senescence of human fibroblasts induced by oncogenic Raf. Genes Dev 1998, 12:2997-3007.
4. Shi Y., Glynn J., Guilbert L., Cotter T., Bissonnette R., Green D. Role for c-myc in activation-induced apoptotic cell death in T cell hybridomas. Science 1992, 257:212-214.
5. Evan G.I., Wyllie A., Gilbert C., Littlewood T., Land H., Brooks M., et al. Induction of apoptosis in fibroblasts by c-myc protein. Cell 1992, 69:119-128.
6. Schmitt C. Cellular senescence and cancer treatment. Biochim Biophys Acta 2006, 1775:5-20.
7. Kuilman T., Michaloglou C., Mooi W.J., Peeper D.S. The essence of senescence. Genes Dev 2010, 24:2463-2479.
8. Dimri G.P., Lee X., Basile G., Acosta M., Scott G., Roskelley C., et al. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci U S A 1995, 92:9363-9367.
9. Hayflick L., Moorhead P.S. The serial cultivation of human diploid cell strains. Exp Cell Res 1961, 25:585-621.
10. Harley C.B., Futcher A.B., Greider C.W. Telomeres shorten during ageing of human fibroblasts. Nature 1990, 345:458-460.
11. Herbig U., Jobling W., Chen B., Chen D., Sedivy J. Telomere shortening triggers senescence of human cells through a pathway involving ATM, p53, and p21(CIP1), but not p16(INK4a). Mol Cell 2004, 14:501-513.
12. O'Brien W., Stenman G., Sager R. Suppression of tumor growth by senescence in virally transformed human fibroblasts. Proc Natl Acad Sci U S A 1986, 83:8659-8663.
13. Bartkova J., Rezaei N., Liontos M., Karakaidos P., Kletsas D., Issaeva N., et al. Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. Nature 2006, 444:633-637.
14. Di Micco R., Fumagalli M., Cicalese A., Piccinin S., Gasparini P., Luise C., et al. Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication. Nature 2006, 444:638-642.
15. Mallette F.A., Ferbeyre G. The DNA damage signaling pathway connects oncogenic stress to cellular senescence. Cell Cycle 2007, 6:1831-1836.
16. Lee A., Fenster B., Ito H., Takeda K., Bae N., Hirai T., et al. Ras proteins induce senescence by altering the intracellular levels of reactive oxygen species. J Biol Chem 1999, 274:7936-7940.
17. Narita M., Nunez S., Heard E., Narita M., Lin A.W., Hearn S.A., et al. Rb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence. Cell 2003, 113:703-716.
18. Lin A.W., Barradas M., Stone J.C., van Aelst L., Serrano M., Lowe S.W. Premature senescence involving p53 and p16 is activated in response to constitutive MEK/MAPK mitogenic signaling. Genes Dev 1998, 12:3008-3019.
19. Courtois-Cox S., Genther Williams S.M., Reczek E.E., Johnson B.W., McGillicuddy L.T., Johannessen C.M., et al. A negative feedback signaling network underlies oncogene-induced senescence. Cancer Cell 2006, 10:459-472.
20. Collado M., Serrano M. The power and the promise of oncogene-induced senescence markers. Nat Rev Cancer 2006, 6:472-476.
21. Schmitt C.A. Cellular senescence and cancer treatment. Biochim Biophys Acta 2007, 1775:5-20.
22. Fridman A.L., Tainsky M.A. Critical pathways in cellular senescence and immortalization revealed by gene expression profiling. Oncogene 2008, 27:5975-5987.
23. Michaloglou C., Vredeveld L., Soengas M., Denoyelle C., Kuilman T., van der Horst C., et al. BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature 2005, 436:720-724.
24. Braig M., Lee S., Loddenkemper C., Rudolph C., Peters A., Schlegelberger B., et al. Oncogene-induced senescence as an initial barrier in lymphoma development. Nature 2005, 436:660-665.
25. Collado M., Gil J., Efeyan A., Guerra C., Schuhmacher A.J., Barradas M., et al. Tumour biology: senescence in premalignant tumours. Nature 2005, 436:642.
26. Chen Z., Trotman L.C., Shaffer D., Lin H.K., Dotan Z.A., Niki M., et al. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature 2005, 436:725-730.
27. Vafa O., Wade M., Kern S., Beeche M., Pandita T., Hampton G., et al. c-Myc can induce DNA damage, increase reactive oxygen species, and mitigate p53 function: a mechanism for oncogene-induced genetic instability. Mol Cell 2002, 9:1033-1044.
28. Reimann M., Loddenkemper C., Rudolph C., Schildhauer I., Teichmann B., Stein H., et al. The Myc-evoked DNA damage response accounts for treatment resistance in primary lymphomas in vivo. Blood 2007, 110:2996-3004.
29. Reimann M., Lee S., Loddenkemper C., Dorr J.R., Tabor V., Aichele P., et al. Tumor stroma-derived TGF-beta limits myc-driven lymphomagenesis via Suv39h1-dependent senescence. Cancer Cell 2010, 17:262-272.
30. Wajapeyee N., Serra R., Zhu X., Mahalingam M., Green M. Oncogenic BRAF induces senescence and apoptosis through pathways mediated by the secreted protein IGFBP7. Cell 2008, 132:363-374.
31. Scurr L.L., Pupo G.M., Becker T.M., Lai K., Schrama D., Haferkamp S., et al. IGFBP7 is not required for B-RAF-induced melanocyte senescence. Cell 2010, 141:717-727.
32. Acosta J., O'Loghlen A., Banito A., Guijarro M., Augert A., Raguz S., et al. Chemokine signaling via the CXCR2 receptor reinforces senescence. Cell 2008, 133:1006-1018.
33. Kuilman T., Michaloglou C., Vredeveld L.C., Douma S., van Doorn R., Desmet C.J., et al. Oncogene-induced senescence relayed by an interleukin-dependent inflammatory network. Cell 2008, 133:1019-1031.
34. Coppe J.P., Patil C.K., Rodier F., Sun Y., Munoz D.P., Goldstein J., et al. Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol 2008, 6:2853-2868.
35. Rodier F., Coppe J.P., Patil C.K., Hoeijmakers W.A., Munoz D.P., Raza S.R., et al. Persistent DNA damage signalling triggers senescence-associated inflammatory cytokine secretion. Nat Cell Biol 2009, 11:973-979.
36. Xue W., Zender L., Miething C., Dickins R.A., Hernando E., Krizhanovsky V., et al. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 2007, 445:656-660.
37. Meyer N., Penn L.Z. Reflecting on 25 years with MYC. Nat Rev Cancer 2008, 8:976-990.
38. Kroemer G., Pouyssegur J. Tumor cell metabolism: cancer's Achilles' heel. Cancer Cell 2008, 13:472-482.
39. Dang C.V., O'Donnell K.A., Zeller K.I., Nguyen T., Osthus R.C., Li F. The c-Myc target gene network. Semin Cancer Biol 2006, 16:253-264.
40. Eilers M., Eisenman R.N. Myc's broad reach. Genes Dev 2008, 22:2755-2766.
41. Staller P., Peukert K., Kiermaier A., Seoane J., Lukas J., Karsunky H., et al. Repression of p15INK4b expression by Myc through association with Miz-1. Nat Cell Biol 2001, 3:392-399.
42. Wu S., Cetinkaya C., Munoz-Alonso M.J., von der Lehr N., Bahram F., Beuger V., et al. Myc represses differentiation-induced p21CIP1 expression via Miz-1-dependent interaction with the p21 core promoter. Oncogene 2003, 22:351-360.
43. Seoane J., Le H.V., Massague J. Myc suppression of the p21(Cip1) Cdk inhibitor influences the outcome of the p53 response to DNA damage. Nature 2002, 419:729-734.
44. Grandori C., Wu K.J., Fernandez P., Ngouenet C., Grim J., Clurman B.E., et al. Werner syndrome protein limits MYC-induced cellular senescence. Genes Dev 2003, 17:1569-1574.
45. Feldser D.M., Greider C.W. Short telomeres limit tumor progression in vivo by inducing senescence. Cancer Cell 2007, 11:461-469.
46. Bouchard C., Lee S., Paulus-Hock V., Loddenkemper C., Eilers M., Schmitt C.A. FoxO transcription factors suppress Myc-driven lymphomagenesis via direct activation of Arf. Genes Dev 2007, 21:2775-2787.
47. Wu K.J., Grandori C., Amacker M., Simon-Vermot N., Polack A., Lingner J., et al. Direct activation of TERT transcription by c-MYC. Nat Genet 1999, 21:220-224.
48. Campaner S., Doni M., Hydbring P., Verrecchia A., Bianchi L., Sardella D., et al. Cdk2 suppresses cellular senescence induced by the c-myc oncogene. Nat Cell Biol 2010, 12:1-14. 54-9; su.
49. Christophorou M.A., Martin-Zanca D., Soucek L., Lawlor E.R., Brown-Swigart L., Verschuren E.W., et al. Temporal dissection of p53 function in vitro and in vivo. Nat Genet 2005, 37:718-726.
50. Land H., Parada L.F., Weinberg R.A. Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes. Nature 1983, 304:596-602.
51. Ruggero D., Montanaro L., Ma L., Xu W., Londei P., Cordon-Cardo C., et al. The translation factor eIF-4E promotes tumor formation and cooperates with c-Myc in lymphomagenesis. Nat Med 2004, 10:484-486.
52. Schmitt C.A., Fridman J.S., Yang M., Baranov E., Hoffman R.M., Lowe S.W. Dissecting p53 tumor suppressor functions in vivo. Cancer Cell 2002, 1:289-298.
53. Mantovani A., Sozzani S., Locati M., Allavena P., Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 2002, 23:549-555.
54. Savill J., Fadok V. Corpse clearance defines the meaning of cell death. Nature 2000, 407:784-788.
55. Huynh M.L., Fadok V.A., Henson P.M. Phosphatidylserine-dependent ingestion of apoptotic cells promotes TGF-beta1 secretion and the resolution of inflammation. J Clin Invest 2002, 109:41-50.
56. Guney I., Wu S., Sedivy J.M. Reduced c-Myc signaling triggers telomere-independent senescence by regulating Bmi-1 and p16(INK4a). Proc Natl Acad Sci U S A 2006, 103:3645-3650.
57. van Riggelen J., Muller J., Otto T., Beuger V., Yetil A., Choi P.S., et al. The interaction between Myc and Miz1 is required to antagonize TGFbeta-dependent autocrine signaling during lymphoma formation and maintenance. Genes Dev 2010, 24:1281-1294.
58. Felsher D.W. MYC inactivation elicits oncogene addiction through both Tumor cell-intrinsic and host-dependent mechanisms. Genes Cancer 2010, 1:597-604.
59. Wu C.H., van Riggelen J., Yetil A., Fan A.C., Bachireddy P., Felsher D.W. Cellular senescence is an important mechanism of tumor regression upon c-Myc inactivation. Proc Natl Acad Sci U S A 2007, 104:13028-13033.
60. Rakhra K., Bachireddy P., Zabuawala T., Zeiser R., Xu L., Kopelman A., et al. CD4(+) T cells contribute to the remodeling of the microenvironment required for sustained tumor regression upon oncogene inactivation. Cancer Cell 2010, 18:485-498.
61. Lauber K., Bohn E., Krober S.M., Xiao Y.J., Blumenthal S.G., Lindemann R.K., et al. Apoptotic cells induce migration of phagocytes via caspase-3-mediated release of a lipid attraction signal. Cell 2003, 113:717-730.
62. Schlee M., Holzel M., Bernard S., Mailhammer R., Schuhmacher M., Reschke J., et al. C-myc activation impairs the NF-kappaB and the interferon response: implications for the pathogenesis of Burkitt's lymphoma. Int J Cancer 2007, 120:1387-1395.
63. Lin H.K., Bergmann S., Pandolfi P.P. Cytoplasmic PML function in TGF-beta signalling. Nature 2004, 431:205-211.
64. Massague J. TGFbeta in cancer. Cell 2008, 134:215-230.
65. Siegel P.M., Massague J. Cytostatic and apoptotic actions of TGF-beta in homeostasis and cancer. Nat Rev Cancer 2003, 3:807-821.
66. Ikushima H., Todo T., Ino Y., Takahashi M., Miyazawa K., Miyazono K. Autocrine TGF-beta signaling maintains tumorigenicity of glioma-initiating cells through Sry-related HMG-box factors. Cell Stem Cell 2009, 5:504-514.
67. Tan T.T., Coussens L.M. Humoral immunity, inflammation and cancer. Curr Opin Immunol 2007, 19:209-216.
68. Dave S.S., Wright G., Tan B., Rosenwald A., Gascoyne R.D., Chan W.C., et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 2004, 351:2159-2169.
69. Steidl C., Lee T., Shah S.P., Farinha P., Han G., Nayar T., et al. Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. N Engl J Med 2010, 362:875-885.
70. Lenz G., Wright G., Dave S.S., Xiao W., Powell J., Zhao H., et al. Stromal gene signatures in large-B-cell lymphomas. N Engl J Med 2008, 359:2313-2323.
71. Schmitt C.A., Fridman J.S., Yang M., Lee S., Baranov E., Hoffman R.M., et al. A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy. Cell 2002, 109:335-346.
72. te Poele R.H., Okorokov A.L., Jardine L., Cummings J., Joel S.P. DNA damage is able to induce senescence in tumor cells in vitro and in vivo. Cancer Res 2002, 62:1876-1883.
73. Haugstetter A.M., Loddenkemper C., Lenze D., Grone J., Standfuss C., Petersen I., et al. Cellular senescence predicts treatment outcome in metastasised colorectal cancer. Br J Cancer 2010, 103:505-509.